Bullous Pemphigoid (Dermatology) - Drugs in Development, 2021
Summary This latest Pharmaceutical and Healthcare disease pipeline guide Bullous Pemphigoid - Drugs In Development, 2021, provides an overview of the Bullous Pemphigoid (Dermatology) pipeline landscape.
Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. The disease can be fatal, particularly in patients who are debilitated. Symptoms include intense itching and burning sensation of the skin. It most commonly occurs in people older than age 60. Treatment includes anti-inflammatory and immunosuppressant.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Bullous Pemphigoid - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Bullous Pemphigoid (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bullous Pemphigoid (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 8, 1, 3, 1 and 1 respectively.
Bullous Pemphigoid (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Bullous Pemphigoid (Dermatology). - The pipeline guide reviews pipeline therapeutics for Bullous Pemphigoid (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Bullous Pemphigoid (Dermatology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Bullous Pemphigoid (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Bullous Pemphigoid (Dermatology)
Reasons to Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Bullous Pemphigoid (Dermatology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Bullous Pemphigoid (Dermatology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 184.108.40.206) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 220.127.116.11) - Janus kinase 2 is a non-receptor tyrosine...
Wilson Disease - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Wilson Disease - Drugs In Development, 2021, provides an overview of the Wilson Disease (Genetic Disorders) pipeline landscape. Wilson disease is a rare autosomal recessive...
Ankylosing Spondylitis (Bekhterev’s Disease) (Musculoskeletal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis - Drugs In Development, 2021, provides an overview of the Ankylosing Spondylitis (Musculoskeletal Disorders)...
The anatomic pathology market is projected to reach USD 49.1 billion by 2026 from USD 35.1 billion in 2021, at a CAGR of 7.0%. The growth of the anatomic pathology market is majorly driven by the high incidence of cancer and other target diseases, recommendations for cancer screening, availability of reimbursement, and the growing focus on...
269 pages •
By The Business Research Company
• Aug 2021
Anatomic Pathology Equipment and Consumables Market Opportunities And Strategies To 2030: COVID-19 Growth And Change provides the strategists, marketers and senior management with the critical information they need to assess the global anatomic pathology equipment and consumables market as it emerges from the COVID 19 shut down. Description: Where...
Respiratory Syncytial Virus Prophylaxis - Global Drug Forecast and Market Analysis to 2030 Summary Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae.The most common clinical scenario for RSV is an...
Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease - Drugs in Development, 2021, provides an overview of the Non Alcoholic Fatty Liver Disease (Gastrointestinal)...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
Melanoma - Epidemiology Forecast to 2029 Summary Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of the skin (World Health Organization, 2017).Melanocytes are embryological derivatives of neural crest tissue, and...
Melanoma - Global Drug Forecast and Market Analysis to 2029 Summary Melanoma of the skin is a serious and aggressive form of cancer originating from melanocytes, the pigment cells in skin, and can develop anywhere on the body.Although melanoma has high survivability, it remains a significant health...
Health Care Provider
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.